BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often cancer-free at five years compared to those given dose-escalated external beam radiation therapy. That’s the finding of the multi-center randomized controlled ASCENDE-RT* trial—the first and so far only study to compare LDR-PB with any other method of radiation delivery. William James Morris MD, a clinical professor at the Vancouver Cancer Centre, Canada, presented data to the ESTRO 2015 Forum and spoke to Oncology Times reporter Sarah Maxwell.
You may also like...
Diabetes increases risk of breast and colon cancer 4 Oct, 2013 Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time 24 Mar, 2015 Video: Txt2Stop: Text Messaging Doubled Smoking Quit Rates 5 Jul, 2011 World Malaria Day 2012: Social Solutions Bring Malaria Under Control 24 Apr, 2012
- Previous story Brachytherapy Improves Survival for Inoperable Early-Stage Endometrial Cancer
- Next story ESTRO 2015 Round-up with President Philip Poortmans
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014